The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.

Within a cohort of >600 000 individuals without prior mitral valve intervention, 5.9%–6.8% and 1.6%–1.7% of men and women, had moderate and severe MR. Like severe MR, at the time of investigation, ...